Showing results (41-50 of 99) with videos related to
Sort By:
Pageof 10
Journal of Psychiatric Research|August 5, 2014
Association between the common functional FKBP5 variant (rs1360780) and brain structure in a non-clinical populationTakashi Fujii, Miho Ota, Hiroaki Hori, et al.Journal of Affective Disorders|October 1, 2013
Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study)Kunitoshi Kamijima, Teruhiko Higuchi, Jun Ishigooka, et al.Psychiatry and Clinical Neurosciences|August 23, 2020
Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depressionTadafumi Kato, Jun Ishigooka, Mari Miyajima, et al.International Journal of Psychiatry in Clinical Practice|June 12, 2014
Revised psychopharmacological algorithms for the treatment of mood disorders in JapanNobutaka Motohashi, Kunihiko Shioe, Jun Nakamura, et al.Journal of Psychiatric Research|August 6, 2010
Possible association of the semaphorin 3D gene (SEMA3D) with schizophreniaTakashi Fujii, Hirofumi Uchiyama, Noriko Yamamoto, et al.Psychiatry and Clinical Neurosciences|May 21, 2013
Validation of computer-administered clinical rating scale: Hamilton Depression Rating Scale assessment with Interactive Voice Response technology--Japanese versionHiroshi Kunugi, Norie Koga, Miyako Hashikura, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 22, 2012
Possible impact of ADRB3 Trp64Arg polymorphism on BMI in patients with schizophreniaDaimei Sasayama, Hiroaki Hori, Toshiya Teraishi, et al.Journal of Affective Disorders|April 2, 2017
A personality-based latent class typology of outpatients with major depressive disorder: association with symptomatology, prescription pattern and social functionHiroaki Hori, Toshiya Teraishi, Anna Nagashima, et al.BMC Psychiatry|March 17, 2016
A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophreniaYoshio Hirayasu, Shin-Ichi Sato, Hideaki Takahashi, et al.Neuropsychiatric Disease and Treatment|August 25, 2021
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension StudyMasaomi Iyo, Jun Ishigooka, Masatoshi Nakamura, et al.Pageof 10